Hepln-13
Hepln-13 is a potent and orally active Hepsin inhibitor with an IC50 of 0.33 μM. Hepln-13 can be used for the research of metastatic prostate cancer[1].
Product Specifications
CAS Number
[64369-13-7]
Product Name Alternative
Clodantoin,Xenazoic acid; CV58913
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Ser/Thr Protease
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/hepln-13.html
Purity
99.34
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
BrC1=CC=C(C=C1)C(N2)NC3=C4C2=CC=CC4=CC=C3
Molecular Formula
C17H13BrN2
Molecular Weight
325.20
Precautions
H302, H315, H319, H335
References & Citations
[1]Tang X, et al. Targeted inhibition of cell-surface serine protease Hepsin blocks prostate cancer bone metastasis. Oncotarget. 2014;5 (5) :1352-1362.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Rabbit Monoclonal FCAR/CD89 Antibody (14A8 (14.1)) [PerCP] - Chimeric](https://cdn.genprice.uk/genprice/uk/genprice4.webp)
NBP3-20161PCP 0.1 mL
Rabbit Monoclonal FCAR/CD89 Antibody (14A8 (14.1)) [PerCP] - Chimeric
Ask
View Details 
GTR15328474 1 Vial
Lentiviral human RAB2B shRNA (UAS) - Lentiviral human RAB2B shRNA (UAS) plasmid
Ask
View Details 